Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain
Vaccines · 11.10.2024 · 12 (10) · 1160
DOI: 10.3390/vaccines12101160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 11.10.2024. Verfasst von Sara Jimeno Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Pediatría, Hospital HM Puerta del Sur, HM Hospitales, 28938 Madrid, Spain. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease. Although clinical trials have demonstrated the efficacy of Nirsevimab in preventing severe RSV disease, evidence regarding its performance in real-world clinical settings is still limited due to its recent introduction. This study aims to fill this knowledge gap by evaluating the impact of Nirsevimab in a cohort of infants and determining its effectiveness in reducing the burden of RSV disease.
Methods
A retrospective study of RSV hospitalizations was conducted in children under six months of age, between 1 October and 31 March, across four seasons: pre-COVID (2018–2019), COVID (2019–2020), post-COVID pre-Nirsevimab (2022–2023), and Nirsevimab season (2023–2024).
Results
Nirsevimab demonstrated significant efficacy in reducing RSV-related hospitalizations in infants under six months of age. During the 2023/2024 season, following the introduction of Nirsevimab, there was a substantial reduction in RSV-related lower respiratory tract infection (LRTI) hospitalizations. Among infants under 3 months of age, hospitalizations decreased by 79.3% (IRR: 0.21, 95% CI: 0.12–0.34). In infants aged 3 to 6 months, there was a 66.9% reduction (IRR: 0.33, 95% CI: 0.15–0.64). Additionally, Nirsevimab decreased the severity of RSV cases with LRTI who required the support of equipment for sanitary use, further reducing overall healthcare burden.
Conclusions
These results underscore Nirsevimab’s vital role in preventing severe RSV infections and hospitalizations, especially among the most vulnerable infants, positioning it as a critical advancement in pediatric respiratory care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Pediatría, Hospital HM Puerta del Sur, HM Hospitales, 28938 Madrid, Spain.
- Unidad de Vacunas, HM Hospitales, 28938 Madrid, Spain.
- Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, 28692 Madrid, Spain.
- Instituto de Investigación Sanitaria HM Hospitales, 28015 Madrid, Spain.
- Departamento de Unidad de Análisis de Datos, Fundación de Investigación HM Hospitales, Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, 28692 Madrid, Spain.
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
ORCID-Profile: Sara Jimeno Ruiz, Adrián Peláez, Silvina Natalini Martínez
Zitieren
APA
Jimeno Ruiz, S., Peláez, A., Labourt, A., Acuña, F. M., Linares, L., Llana Martín, I., Calle Gómez, Á., & Martínez, S. N. (2024). Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines, 12(10), 1160. https://doi.org/10.3390/vaccines12101160
Vancouver
Jimeno Ruiz S, Peláez A, Labourt A, Acuña FM, Linares L, Llana Martín I, et al. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines. 2024;12(10):1160. doi:10.3390/vaccines12101160
BibTeX
@article{JimenoRuiz2024,
author = {Jimeno Ruiz, Sara and Peláez, Adrián and Labourt, Agustín and Acuña, Florencia Mercedes and Linares, Lucía and Llana Martín, Isabel and Calle Gómez, Ángeles and Martínez, Silvina Natalini},
title = {Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {10},
pages = {1160},
doi = {10.3390/vaccines12101160}
}
EUVIMED